Dovilė Jurevičiūtė – Biomapas Academy Alumni

How did you decide to participate in the Biomapas Academy?

The first thing that caught my attention was the Biomapas Academy poster hanging on my university’s bulletin board. Shortly afterwards, the faculty management shared Biomapas’ invitation to register for the first Biomapas Academy. I wanted to learn more about this company, so I decided to take my chances and apply to the Academy. I was thrilled when I received a call with the happy news that I had successfully passed the selection process and was invited to attend the Academy.

 

What was your experience during the three months?

I listened to many interesting lectures, during which we got to know the company and its areas of activity. We listened to lectures on clinical trials and their organization, pharmacovigilance, regulatory affairs, bioethics, drug registration, and more. I believe that the knowledge gained at the Academy is valuable and helpful for all participants of the Academy and their future careers.

What did the future hold for you after the Academy?

I mainly was interested in pharmacovigilance, so we agreed on an internship in this department during the summer. Interesting fact: the first Biomapas poster I saw was about pharmacovigilance! And the best thing is that after the internship, I was able to join and become a part of this great team. I am happy to be here and to learn from real professionals in this field.

 

What would you say to the future participants?

I want to encourage everyone who is thinking about participating in the Biomapas Academy. Being at the Academy is exciting and worthwhile. By joining the Academy, you will broaden your horizons, learn from global professionals, improve your life sciences knowledge, and gain valuable experience. I wish good luck to all participants. See you soon at Biomapas!

Biomapas Academy

What is Clinical Research? Regulatory Affairs? Pharmacovigilance?

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

The CIS Region: Excellent Potential for Patient Recruitment but is there any Risk to Quality?

The CIS Region: Excellent Potential for Patient Recruitment but is there any Risk to Quality?

The number of clinical trials worldwide is increasing more than 10% each year due to the new diseases, further research for better health products and development of new drugs. Though, for a successful clinical trial, there is a major challenge – patient recruitment, which is essential and the most challenging factor due to the increasing number of new clinical trials. In order to achieve the required patient recruitment, sponsors are looking for different solutions.

read more
Running a clinical trial in the Baltic states

Running a clinical trial in the Baltic states

In the past five years, an average of 175 clinical trials are being initiated in the Baltic states each year. An average of 64,8% of the population in the Baltic states are in the age from 15 to 65 years old, the main target audience for clinical trials. Furthermore, a large pool of treatment-naïve subjects is available compared to other EU countries or the US. Patients with special therapeutic diseases are transferred to the main central hospitals.

read more
Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

On 29th March 2017 UK submitted the notification of its intention to withdraw from the EU. This means that UK will become a ‘third country’ from 30th March’19. Even though leaving the EU with a deal remains the Government’s top priority, UK drug agency is publishing a series of guidance documents for industry and other stakeholders covering the proposed arrangements for the regulation of medicines, medical devices and clinical trials, if UK leaves EU with no deal.

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information